MannKind (NASDAQ:MNKD) Hits New 12-Month Low on Disappointing Earnings

MannKind Corporation (NASDAQ:MNKD)’s share price hit a new 52-week low on Thursday following a weaker than expected earnings announcement. The company traded as low as $3.29 and last traded at $3.50, with a volume of 36513820 shares traded. The stock had previously closed at $5.54.

The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). The company had revenue of $111.96 million during the quarter, compared to the consensus estimate of $99.85 million. MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.MannKind’s revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 earnings per share.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

Analyst Upgrades and Downgrades

MNKD has been the topic of several analyst reports. Wall Street Zen cut MannKind from a “buy” rating to a “hold” rating in a research report on Saturday. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $3.50 price objective (down from $7.50) on shares of MannKind in a research note on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a research note on Thursday, January 22nd. Truist Financial set a $9.00 price target on shares of MannKind in a research report on Monday, November 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of MannKind in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, MannKind currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.21.

Insider Transactions at MannKind

In other MannKind news, CEO Michael Castagna sold 65,804 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $6.01, for a total value of $395,482.04. Following the completion of the sale, the chief executive officer owned 2,504,792 shares of the company’s stock, valued at $15,053,799.92. This represents a 2.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of MannKind stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the transaction, the insider directly owned 985,007 shares in the company, valued at $6,235,094.31. This trade represents a 4.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 262,846 shares of company stock worth $1,546,840 in the last 90 days. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On MannKind

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd boosted its position in MannKind by 108.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 2,927 shares during the period. Quaker Wealth Management LLC lifted its stake in shares of MannKind by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 14,000 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in MannKind during the 4th quarter valued at about $45,000. Huntington National Bank grew its position in MannKind by 420.0% during the 4th quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Burkett Financial Services LLC purchased a new position in MannKind in the 4th quarter worth approximately $59,000. Institutional investors own 49.55% of the company’s stock.

MannKind Trading Up 1.2%

The stock has a 50 day simple moving average of $5.55 and a 200 day simple moving average of $5.35. The firm has a market capitalization of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.